Novartis Pharmaceuticals Canada Inc. has complied with a request from Health Canada to cease the sales and marketing in Canada of Prexige, a COX-2 selective inhibitor for the treatment of osteoarthritis, effective immediately.
Novartis Pharmaceuticals Canada Inc. has complied with a request from Health Canada to cease the sales and marketing in Canada of Prexige, a COX-2 selective inhibitor for the treatment of osteoarthritis, effective immediately.